Alkermes plc
NASDAQ:ALKSBiotechnology
+$0.79 today
- Market cap
- $7.87B
- Beta
- 0.33
- P/E (TTM)
- 49.1
- EPS (TTM)
- $0.92
Volume 1.39M
Average 2.33M
ALKS Sales of Investments
Cash received from selling or redeeming investments.
Alkermes plcNASDAQ: ALKS
Sales of Investments · Q3 FY2026 · quarter ended Sep 2026
Sales of investments dips below year-ago levels
Q3 FY2026 sales of investments of $43.99M fell 64.9% year over year, behind the +19.2% change in trailing-twelve-month sales of investments. Sequentially, it rose 119.0% from the prior quarter. Over 3 fiscal years it compounded at +35.3% a year.
Context
- Sales of investments amounted to 47.3% of revenue in FY2025, up 27.3 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -64.9% toward the trailing-twelve-month pace of +19.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 697.49M USD
- Year-over-year change
- +124.8%
- 4-year CAGR
- +24.0%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 697.49M | +124.8% |
| FY2024 | 2024-12-31 | 310.29M | -12.7% |
| FY2023 | 2023-12-31 | 355.52M | +26.2% |
| FY2022 | 2022-12-31 | 281.63M | -4.5% |
| FY2021 | 2021-12-31 | 295.01M | — |
Sales of Investments vs competitors
How ALKS compares with its peers on the latest reported figures
- ALKS's LTM Sep 2026 sales of investments of $483.79M is the 5th largest of the 7 companies compared; the peer median is $927.35M.
- Its year-over-year change of +19.2% is the 4th highest of 6, against a peer median of +92.5%.
- Sales of investments amounts to 27.6% of revenue for ALKS, versus a peer median of 64.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.83B | +92.5% | +183.0% | 60.0% | |
| LTM Sep 2026 | $2.8B | +161.1% | +28.7% | 75.6% | |
| LTM Jun 2026 | $1.36B | +148.4% | +59.6% | 163.8% | |
| LTM Jun 2026 | $494.34M | +11.6% | +4.2% | 43.4% | |
| LTM Sep 2026 | $483.79M | +19.2% | +35.3% | 27.6% | |
| LTM Mar 2026 | $151.03M | -60.2% | -19.5% | 69.3% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ALKS) | $927.35M | +92.5% | +28.7% | 64.7% | |
Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.17M) | (158.27M) | 355.76M | 367.07M | 241.66M |
| Depreciation & Amortization | 78.65M | 77.86M | 74.93M | 28.53M | 27.17M |
| Deferred Income Tax | 5.08M | (32.8M) | (99.9M) | 40.52M | 28.77M |
| Stock-Based Compensation | 87.62M | 94.25M | 100.91M | 96.64M | 98.72M |
| Change in Working Capital | (25.55M) | 12.71M | (36.66M) | (98.15M) | 119.12M |
| Accounts Receivables | (38.01M) | 25.25M | (44.51M) | (56.34M) | 55.49M |
| Inventory | (24.77M) | (31.02M) | (2.71M) | 3.09M | (14.06M) |
| Accounts Payables | 43.31M | 15.53M | 23.01M | (57.97M) | 100.89M |
| Other Working Capital | (6.08M) | 2.95M | (12.45M) | 13.06M | (23.2M) |
| Other Non-Cash Items | 4.08M | 27.28M | 6.33M | 4.51M | 5.31M |
| Operating Cash Flow | 101.72M | 21.04M | 401.35M | 439.12M | 520.75M |
| Capital Expenditures | (29.02M) | (38.26M) | (48.05M) | (33.48M) | (40.42M) |
| Acquisitions (Net) | (713K) | 485K | 0 | 97.98M | 2.79M |
| Purchases of Investments | (340.42M) | (309.67M) | (254.47M) | (486.55M) | (364.37M) |
| Sales of Investments | 295.01M | 281.63M | 355.52M | 310.29M | 697.49M |
| Other Investing Activities | 8.94M | 1.27M | 354K | 461K | 0 |
| Investing Cash Flow | (66.2M) | (64.54M) | 53.36M | (111.31M) | 295.5M |
| Debt Repayment | 20.32M | (3M) | (3M) | (291.79M) | 0 |
| Common Stock Issued | 25.32M | 19.63M | 16.76M | 27.57M | 43.41M |
| Common Stock Repurchased | (16.57M) | (18.2M) | (28.47M) | (200.28M) | (31.03M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (275M) | (29.64M) | 0 |
| Financing Cash Flow | 29.07M | (1.57M) | (289.71M) | (494.14M) | 12.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 64.58M | (45.07M) | 165M | (166.32M) | 828.63M |
| Free Cash Flow | 72.7M | (17.21M) | 353.31M | 405.64M | 480.33M |
Alkermes plc
NASDAQ:ALKS
Intrinsic Alpha fair value
Locked
Current Price
$46.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.